Adfrar (adalimumab biosimilar) / Torrent Pharma, Reliance Life Sci - LARVOL DELTA

Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies. (PubMed, Cureus) - "This article reviews current diagnostic and emerging treatment strategies to highlight the evolution from traditional therapies such as aminosalicylates, corticosteroids, and immunomodulators to advanced biologic agents like infliximab and adalimumab. Emerging biological therapies, including vedolizumab and ustekinumab, show promise, while novel small molecule therapies such as Janus kinase (JAK) inhibitors are under investigation for potential use in the pediatric population...Future recommendations emphasize the importance of structured transition programs bridging pediatric and adult care, regular updates to clinical guidelines, and the integration of precision medicine to personalize treatment plans. Continued research and collaboration are essential for advancing the understanding and management of PIBD, ensuring that pediatric patients benefit from the most effective, evidence-based care available."

Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pediatrics • Transplantation • Ulcerative Colitis

Current Knowledge of Biologics in Treatment of Noninfectious Uveitis. (PubMed, J Ocul Pharmacol Ther) - "Other drugs include anti-CD20 inhibitors (rituximab), interleukin-6R-inhibitor (tocilizumab), Interleukin-1R-inhibitor (anakinra), Iinterleukin-2-inhibitor (daclizumab), and the list is further increasing. New advances in biologics are the biosimilar molecules, which are biological products that are highly similar to the reference product, and they include Infimab (biosimilar of infliximab), Exemptia or Adfrar (biosimilar of adalimumab), and Intacept or Etacept (biosimilar of etanercept)...Thus, biologics are the future of uveitis treatment with promising results. This article aims to summarize the current knowledge on biologics and their clinical utility in the management of NIU."

Journal • Ankylosing Spondylitis • Immunology • Inflammation • Inflammatory Arthritis • Ocular Inflammation • Oncology • Ophthalmology • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Uveitis • IL1R1 • IL2 • IL6R

Torrent launches world's second biosimilar of generic auto-immune drug (Business Standard) - "...Torrent Pharmaceuticals launched its biosimilar for Adalimumab, a therapy for the treatment of auto immune disorders like rheumatoid arthritis etc, across India today...According to the terms of the agreement, Reliance Life Sciences will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for a period of 10 years...Torrent has launched new generation Hepatitis C antiviral Sofosbuvir under the brand name Sofocruz, a combination of Sofosbuvir and Ledipasvir called Sofocruz LP and Daclatasvir (brand name Dclacruz)."

Biosimilar launch • Generic launch • Licensing / partnership • Ankylosing Spondylitis • Biosimilar • Hepatitis C Virus • Inflammatory Bowel Disease • Psoriasis • Rheumatoid Arthritis